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It is well accepted that aging is an important contributing factor to the development of osteoarthritis
(OA). The mechanisms responsible appear to be multifactorial and may include an age-related pro-in-
ﬂammatory state that has been termed “inﬂamm-aging.” Age-related inﬂammation can be both systemic
and local. Systemic inﬂammation can be promoted by aging changes in adipose tissue that result in
increased production of cytokines such as interleukin (IL)-6 and tumor necrosis factor-a (TNFa).
Numerous studies have shown an age-related increase in blood levels of IL-6 that has been associated
with decreased physical function and frailty. Importantly, higher levels of IL-6 have been associated with
an increased risk of knee OA progression. However, knockout of IL-6 in male mice resulted in worse age-
related OA rather than less OA. Joint tissue cells, including chondrocytes and meniscal cells, as well as the
neighboring infrapatellar fat in the knee joint, can be a local source of inﬂammatory mediators that
increase with age and contribute to OA. An increased production of pro-inﬂammatory mediators that
include cytokines and chemokines, as well as matrix-degrading enzymes important in joint tissue
destruction, can be the result of cell senescence and the development of the senescence-associated
secretory phenotype (SASP). Further studies are needed to better understand the basis for inﬂamm-
aging and its role in OA with the hope that this work will lead to new interventions targeting inﬂam-
mation to reduce not only joint tissue destruction but also pain and disability in older adults with OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Aging is one of the most prominent risk factors for osteoarthritis
(OA). Numerous studies have documented an increase in radio-
graphic and symptomatic hand, hip, spine, and knee OA with
increasing age (reviewed in1). Due to its prevalence, OA is a major
cause of pain and disability in older adults2. Given the recent and
dramatic increase in the older adult population in developed coun-
tries, the discovery of interventions that target the aging aspects of
OA would have signiﬁcant public health impact. This will require a
better mechanistic understanding of how aging contributes to the
development of OA, including the role of age-related inﬂammation.
Lopez-Otin et al.3 have recently proposed nine candidate hall-
marks of aging that include genomic instability, telomere attrition,
epigenetic alterations, loss of proteostasis, deregulated nutrient
sensing, mitochondrial dysfunction, cellular senescence, stem cellR.F. Loeser, Thurston Arthritis
hurston Building, CB #7280,
2; Fax: 1-919-966-1739.
Loeser).
ternational. Published by Elsevier Lexhaustion, and altered intercellular communication. Several of
these processes contribute to the aging phenotype by promoting a
low-grade pro-inﬂammatory state that will be discussed further
below. The emergence of evidence to support a role for low-grade
chronic inﬂammation in aging and age-related conditions suggests
that inﬂammation could be an important link between aging andOA.
In this review, we will discuss various mechanisms by which an
age-related pro-inﬂammatory state may contribute to the devel-
opment of OA. OA is a clearly not just aging of the joints but rather is
a multifactorial condition with a number of risk factors including
joint injury, obesity, abnormal mechanics, genetics, gender, and so
on. We would postulate that factors related to aging that promote
both a systemic and a local pro-inﬂammatory state do not directly
cause OA but rather serve as contributing factors to the develop-
ment and progression of the disease as well as to increased pain
and reduced physical function (Fig. 1).Aging and systemic inﬂammation
Studies demonstrating an increase with age in blood levels of C-
reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor-td. All rights reserved.
Fig. 1. Potential age-related changes that increase systemic and local inﬂammation and promote the development of OA. Systemic levels of multiple pro-inﬂammatory mediators, in
particular IL-6 and TNF-a, increase with age due to production by adipose tissue which becomes more inﬂammatory with age and due to a chronic low-grade pro-inﬂammatory
state that has been termed “inﬂamm-aging”. Local changes within the joint have been associated with increased production of inﬂammatory mediators as has cell senescence
through development of the SASP.
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chronic, systemic, low-grade inﬂammation contributes to the
development of chronic diseases of aging, including dementia and
cardiovascular disease4e7. The strongest association of these in-
ﬂammatory markers with age-related disease, as well as with a
decline in physical function, has been seen with IL-68. Epidemio-
logic studies have also shown a link between systemic markers of
inﬂammation, including IL-6, and OA. Elevated levels of CRP and IL-
6 were found in people with OA of the knee and levels of these pro-
inﬂammatory markers were related to risk of progression9,10.
Likewise, a study of a cohort of 90-year-olds found an association
between the absence of knee OA and lower production of IL-6when
whole-blood samples were stimulated with lipopolysaccharide11.
Levels of systemic markers of inﬂammation have been shown to
correlate with pain and function in older adults with knee OA.
Stannus et al.12 noted an increase in serum TNF-a and high
sensitivity(hs)-CRP corresponding to increased knee pain over a
5 year study, and Penninx et al.13 reported that high levels of the
soluble receptors for TNF-a correlated with decreased physical
ability in older adults with knee OA. Although higher levels of TNF-
a soluble receptors may seem to represent an increase in anti-
inﬂammatory activity, previous studies have suggested they are a
more stable marker of increased TNF-a activity than measures of
TNF-a in serum which can be quite labile. Thus systemic inﬂam-
mation in older adults with OA may not only be a factor associated
with progression of OA but also with pain and physical function.
Franceschi et al.14 coined the term “inﬂamm-aging” to describe
the pro-inﬂammatory state that occurs with increasing age.
Inﬂamm-aging was originally proposed to be the result of an
accumulation over time of an increased “antigenic load” and the
combined effects fromvarious stressors on the immune system that
resulted in immunosenescence. The macrophage was proposed to
play a central role as a pro-inﬂammatory mediator in this process.
In addition to immunosenescence, subsequent work has tied
inﬂamm-aging to age-related endocrine, metabolic, and nutritional
changes that also promote a pro-inﬂammatory state. These includean increase in fat mass that can be a source of pro-inﬂammatory
mediators, increasing levels of reactive oxygen species that pro-
mote metabolic changes as well as increased activity of inﬂam-
matory mediators, and changes in levels of speciﬁc micro-RNAs
that are involved in the regulation of the NFkB family of pro-
inﬂammatory mediators15e17.
Inﬂamm-aging appears to be much more complex than just an
age-related increase in production of pro-inﬂammatory mediators.
Morrisette-Thomas et al.18 examined levels of 19 inﬂammatory
markers from an ongoing longitudinal study of older adults in Italy
called the InCHIANTI study. They reported a signiﬁcant age-related
increase in pro-inﬂammatory markers, including hsCRP, IL-6, IL-15,
IL-18 andmacrophage inﬂammatory protein-1b (MIP-1b) while the
anti-inﬂammatory cytokine IL-10 was found to decrease as age
increased. However, they also noted an increase with age in several
anti-inﬂammatory markers including IL-1 receptor antagonist (IL-
1RA), soluble glycoprotein 130 (prevents IL-6 from binding to its
membrane receptor), and soluble TNF receptors I and II (sTNFRI and
sTNFRII).
In order to determine which of the inﬂammatory markers
explained the most variance in the data and to examine the rela-
tionship of these groups of markers to age and chronic diseases
they used principal components analysis (PCA). Two groups of in-
ﬂammatory markers explained 19% and 10% of the total variance
among all the markers. The ﬁrst group (PCA1) included sTNF-R1,
sTNF-RII, IL-6, TNF-a, hsCRP, IL-18, and IL1-RA and increased
levels showed a strong correlation with age (r ¼ 0.56, P < 0.0001).
This group was also predictive of mortality and correlated with a
number of chronic disease states. The second group (PCA2), which
contained markers associated with innate immune system activa-
tion (MCP, IL-8 and IL-12), was weakly correlatedwith age (r¼ 0.08,
P ¼ 0.053) but was more strongly associated with chronic diseases
that included arthritis. Unexpectedly, they found that higher levels
of the markers in the second group were actually protective against
chronic diseases, including arthritis which had an odds ratio of 0.74
(95%CI, 0.58e0.93) per unit change for the scores in PCA2. The
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may stimulate production of anti-inﬂammatory factors and the
balance of these factors in a given individual will determine their
susceptibility to age-related diseases. Of potential relevance, male
mice with a deletion of the IL-6 gene were found to have more
severe age-related OA compared to age-matched wild-type con-
trols rather than less severe OA as might be expected19. Clearly
more work needs to be done in order to better understand the
relationship between biomarkers of inﬂammation and age-related
disease with the understanding that the balance of both pro-
inﬂammatory and anti-inﬂammatory mediators is important to
consider.
Aging and the senescence-associated secretory phenotype
(SASP)
One of the mechanisms by which aging promotes chronic
inﬂammation that could be important in OA is through cell
senescence. Cell senescence was originally used to describe the
state of growth arrest that occurred after extensive proliferation of
ﬁbroblasts induced by multiple passages in culture20. This form of
replicative senescence has been thought to serve as amechanism to
prevent unlimited proliferation of cells that would lead to cancer.
Various markers have been used to identify senescent cells,
including senescence-associated b-galactosidase (SA-b-gal),
increased expression of the cyclin-dependent kinase inhibitor
p16INK4a, and formation of senescence-associated heterochro-
matin (reviewed in21). Cell senescence is not just a phenomenon
observed with cultured cells but rather senescent cells have been
shown to accumulate in various tissues with aging21.
There is surprisingly little in situ data to show that articular
chondrocytes senesce in normal articular cartilage while there is
evidence for senescence in OA cartilage. Price et al.22 compared
normal cartilage fromolder adults with hip fractures to OA cartilage
removed during arthroplasty and found SA-b-gal staining only in
the OA samples. In contrast, Martin and Buckwalter23 did ﬁnd ev-
idence of SA-b-gal and decreased telomere length with age in
cultured chondrocytes from normal joints. Others have also shown
evidence of cell senescence in OA cartilage including a reduction in
telomere length and increased DNA damage24,25 as well as an in-
crease in p16INK4a26. Chondrocytes do not normally proliferate in
the articular cartilage of adults27 making it unlikely that chon-
drocyte senescence would be the result of multiple cycles of cell
proliferation. However, cell proliferation is not a requirement for
cell senescence which can also occur after repetitive stress to tis-
sues and cells28. This mechanism would be very relevant to the
chronic repetitive loading experienced by joint tissues and the
excessive loading associated with the development of OA which
may explain why evidence of chondrocyte senescence has been
detected in OA tissue.
In addition to growth arrest, senescent cells exhibit a number of
other features that include secretion of pro-inﬂammatory cyto-
kines, chemokines, growth factors, and matrix metalloproteinases
(MMPs) which has been referred to as the SASP29,30. The SASP could
promote age-related pathologies, such as OA, by increasing local
levels of pro-inﬂammatory mediators and matrix-degrading en-
zymes. Freund et al.31 composed a list of 83 SASP factors that had
been reported in the literature in studies examining various in-
ducers of cell senescence. The factors were divided by the level of
increase from high (>4 fold) to intermediate (2e4 fold) to small (<2
fold). Interestingly, all of the SASP factors produced at high levels by
senescent cells have been found in OA tissues and/or synovial ﬂuid.
These include GM-CSF, GROa,b,g, IGFBP-7, IL-1a, IL-6, IL-7, IL-8,
MCP-1, MCP-2, MIP1a, MMP-1, MMP-10, and MMP-332e38. Many
of the SASP factors present at intermediate levels, such as ICAM-1,IL-1b, MCP-4, MIF, MMP-13, oncostatin M, RANTES, and TIMP-2
have also been recognized as potential mediators in OA32,35,39e41.
Several recent studies have used a proteomics approach to
describe the secreted proteins or “secretome” produced by either
chondrocytes or cartilage explants from human OA joints42e44 or
from canine and equine cartilage explants stimulated with IL-
1b45,46. Some of the proteins identiﬁed in one or more of these
studies are also on the list of SASP proteins including GROa, IGFBP-
7, IL-8, MMP-1, MMP-2, MMP-3, MMP-14, IGFBP-2, IGFBP-3, IGFBP-
4, IGFBP-5, IGFBP-6, TIMP-1 and TIMP-2. Although these 14 pro-
teins only suggest a partial overlap of the chondrocyte secretome
with the list of 83 SASP factors noted above, it should be noted that
untargeted proteomics analysis tends to ﬁnd the more abundant
proteins in samples and would be less sensitive in detecting many
of the SASP factors such as cytokines, chemokines and growth
factors. Further studies are needed usingmore sensitive assays such
as ELISAs or multiplex cytokine analysis to determine the degree of
overlap between the factors produced by OA chondrocytes and
those considered to be representative of the SASP.
The mechanisms responsible for cell senescence and in partic-
ular for the SASP are still being elucidated but appear to include
DNA damage and activation of the p38 MAP kinase47. Another
consistent ﬁnding has been expression of p16INK4a that activates
the pRB tumor suppressor and promotes formation of senescence-
associated heterochromatin foci which function to silence genes
regulating cell proliferation28. Deletion of cells expressing
p16INK4a in mice was found to prevent the development of age-
related changes in tissues that included muscle, adipose tissue,
and the eye48. As detailed above, chondrocytes in OA have been
found to have evidence of DNA damage that could promote the
development of a senescent phenotype24 and have been shown to
have increased expression of p16INK4a26. Knockdown of p16INK4a
in cultured OA chondrocytes restored matrix gene expression26.
Studies of the role of p16INK4a in promoting the SASP in chon-
drocytes are warranted and would increase the understanding of
the mechanisms by which chondrocyte senescence contributes to a
pro-inﬂammatory state in cartilage.Obesity, adiposity, and inﬂamm-aging
Obesity is a risk factor for OA due to the combined effects of
abnormal joint loading and increased production of adipokines and
other inﬂammatory mediators from fat depots throughout the
body49,50. As people age, there is a decrease in muscle mass and
increase in fat mass51 which could contribute both to mechanical
stress from abnormal joint loading and to an increase in inﬂam-
matory mediators produced by the increased fat mass. Age-related
inﬂammation in adipose tissue has been attributed to senescence of
pre-adipocytes resulting in adipocytes exhibiting the SASP, as well
as from an inﬂux of activated macrophages due to the release of
cytokines and chemokines from stressed pre-adipocytes52.
The contribution of fat to systemic levels of pro-inﬂammatory
mediators and adipokines was investigated by Messier et al.53 in
the IDEA trial where overweight and obese older adults with
symptomatic knee OA were randomly assigned to one of three
intervention groups: intensive diet-induced weight loss and exer-
cise, intensive diet-induced weight loss alone, or exercise alone. At
the conclusion of the 18-month study, there were more signiﬁcant
decreases in circulating IL-6 levels and in total fat mass in partici-
pants assigned to the diet þ exercise and diet groups than the ex-
ercise group. Regardless of intervention group, study participants
who lost at least 10% of their bodyweight saw a greater reduction in
knee compressive force, circulating IL-6, and pain than those who
did not achieve the 10% weight loss goal. The connection between a
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6 support the role of obesity-related systemic inﬂammation in OA.
Additional studies from the same group have shown that in
overweight and obese older adults, the combination of diet-
induced weight loss and physical activity reduced circulating lep-
tin and IL-6 more than physical activity alone54, and that adiposity
is the primary factor that explains poor physical performance in
older adults with metabolic syndrome55. While the latter study did
not focus on OA, the studies to date do provide supporting evidence
for an effect of systemic inﬂammation caused by obesity in older
adults.
In addition to a role in promoting systemic inﬂammation, fat
tissue can also have local effects. The infrapatellar fat pad is a po-
tential local source of adipokines and inﬂammatory mediators
within the knee joint. Distel et al.56 showed in a group of obese
women with knee OA that the infrapatellar fat pad is a source of
adipokines (adiponectin and leptin) as well as inﬂammatory me-
diators (IL-6 and sIL-6R). Relative to aging, Chuckpaiwong et al.57
described a correlation between volume of the infrapatellar fat
pad and the age of OA subjects where the size of the infrapatellar fat
pad increased over the course of a 12-month study. Another group
found that treatment of human articular chondrocytes with re-
combinant leptin or white adipose tissue (WAT) conditioned media
containing leptin increased expression and activation of MMPs and
stimulated collagen release from explant cultures58. The WAT
samples were isolated from the infrapatellar fat pad of human OA
knee joints suggesting that leptin and other factors produced by the
infrapatellar fat pad may contribute to cartilage degradation in
knee OA.
Age-related changes in inﬂammatory mediators in joint
tissues
In addition to aging fat, joint tissues including the cartilage and
meniscus can be a source of pro-inﬂammatory mediators. In an
animal study comparing gene expression in joint tissues from 12-
week old mice and 12-month old mice undergoing either the
destabilization of the medial meniscus (DMM) or sham surgery,
Loeser et al.59 described 493 genes that were differentially regu-
lated between the young and old DMM groups, and 861 genes that
were differentially expressed between young and old sham groups.
Of note from the group of genes showing age-related differences,
expression of IL-33 and three chemokines, CXCL13, CCL8, and CCL5,
were signiﬁcantly up-regulated in the old sham group compared to
the young sham group.
Interleukin 7 (IL-7) is another cytokine that is up-regulated with
age. Long et al.34 found that human articular chondrocytes in
monolayer culture from older donors release higher levels of IL-7
than young donors, and that OA chondrocytes release higher
levels of IL-7 than age-matched normal donors. Chondrocytes
respond to IL-7 treatment by increased levels of MMP-13 and
increased proteoglycan release from cartilage explants. Rubenha-
gen et al.60 also noted an age-related increase in IL-7 in synovial
ﬂuid samples from a cohort of 82 patients with varying degrees of
OA. Likewise, there is evidence for an increase in production of IL-
1b by cultured chondrocytes from older tissue donors61. In contrast,
Peffers et al.62 found a decrease in the RNA levels of IL-1b as well as
IL-8 when comparing metacarpophalangeal cartilage from young
and old horses.
Recent studies have shown that the meniscus may be a source of
inﬂammatory mediators in the joint. However, Brophy et al.63 re-
ported that the pro-inﬂammatory cytokine IL-1b and the matrix-
degrading enzymes ADAMTS-5, MMP-1, MMP-9, and MMP-13
were more highly expressed in meniscal tissue isolated from
young subjects (<40 years old) than from older subjects (>40).These changes may be due to an early inﬂammatory response
promoting repair in young subjects while a low-grade chronic in-
ﬂammatory response inhibits repair in older subjects. Whether
similar soft-tissue structures such as ligaments in the knee also
have increased production of inﬂammatory mediators with age
would be of interest to investigate as would age-related changes in
synovial tissue and the joint capsule.Conclusions
There is epidemiologic as well as biologic evidence to suggest a
link between age-related inﬂammation or “inﬂamm-aging” and the
development of OA. The sources of age-related pro-inﬂammatory
mediators that might contribute to OA include both peripheral
sources, such as adipose tissue that increases with age, as well as
local production within joint tissues. Although cell senescence and
the development of the SASP serves as an attractive mechanism
linking aging, inﬂammation, and OA, there is insufﬁcient evidence
that this occurs with normal aging in joint tissues. Excessive me-
chanical loading of the joint that is severe enough to lead to OAmay
result in stress-induced senescence and increased production of
pro-inﬂammatory mediators but whether this phenotype occurs in
normal aged joints that have not experienced excessive loading is
less clear.
Given that OA is a chronic disease that becomes more prevalent
with age, it is difﬁcult to separate effects of age from disease,
particularly in studies of human tissues. It seems unlikely that any
single pro-inﬂammatory mediator plays a key role in linking aging
and OA. At least in male mice, deletion of IL-6, the cytokine that has
been perhaps most closely related to aging, resulted in more severe
rather than less severe OA19. Future studies will need to examine
the balance of multiple pro-inﬂammatory and anti-inﬂammatory
factors in order to better understand mechanisms by which this
balance is disrupted in aging. Targeting these mechanisms and
restoring a proper balance may help to slow or stop the progression
of age-related chronic conditions including OA.Contributions
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